An analysis of the IBM MarketScan commercial insurance database in the U.S. also failed to identify a significantly higher adjusted risk of Fournier’s gangrene compared to DPP4 inhibitor use (aHR 0.25, 95% CI 0.04–1.74); however, a higher point estimate of risk was noted compared to all non-SGLT2 inhibitor antihyperglycemic medications across diagnosis settings (aHR 1.80, 95% CI 0.53–6.11), leading the authors to conclude uncertainty exists in the risk of this infection against the backdrop of non-SGLT2 inhibitor antidiabetic medications [41]. This evidence concerns the gene SLC5A2 and infection.